After a $10.8 billion sale, a little golf seems reasonable. Mark C. McKenna and his former colleagues had earned a pause. Prometheus Biosciences had been acquired by Merck in June 2023. There were beaches, a few months away from the job, and the agreeable prospect of deciding what came next without quite so many meetings. By March 2024, several of them were together again, launching Mirador Therapeutics. Apparently the fairway could hold their attention only so long.
The return gives McKenna’s career its curious shape. A deal large enough to dominate a résumé became the middle of the story. He had led Prometheus since 2019; now he was founding another company, with familiar colleagues and fresh capital. He called the earlier journey unfinished. The new venture gave that conviction an address in San Diego, a board, and more than $400 million to begin.
It is tempting to read backward from an acquisition and make every earlier decision look inevitable. McKenna’s route resists that treatment. It includes a change of college major, a long apprenticeship inside established businesses, and a move into a startup whose finances were less comfortable than he expected. The neat version fits on a business card. The interesting version has rather more moving parts.
The flight before the financing
He originally went to Arizona State University to study aeronautical engineering. Airplanes interested him; eventually, he decided that interest belonged in the category of hobby. During a Thanksgiving flight home to California, a chance conversation with a Johnson & Johnson employee opened up another possibility. The employee suggested business and offered a card. McKenna switched to marketing, graduated in 2002, and began working at Johnson & Johnson.
There is a satisfying bit of symmetry here: a student interested in aircraft found a different direction while travelling in one. Yet the practical part of the episode is the invitation. Somebody working in a field he had not chosen could imagine him in it. A course change followed. The career that eventually brought him to Mirador began with the willingness to reconsider an earlier plan.
His education later included an MBA at Azusa Pacific University and the Wharton Fellows Program. That combination sits comfortably beside a career spent moving between commercial responsibilities and company leadership. His first degree was in marketing. The people who would join him later brought other expertise. Putting those backgrounds to work together became a recurring feature of his professional life.
A long apprenticeship inside the business
Before Prometheus, there were years at companies with established operations and products. McKenna spent more than a decade at Bausch + Lomb, ultimately becoming senior vice president and general manager of its U.S. Vision Care business. He then served as president of Salix Pharmaceuticals from March 2016 through August 2019. His work involved the unglamorous machinery that keeps a business running: commercial strategy, acquisitions, launches, revenue and margins.
At Salix, strategic acquisitions and product launches helped double revenue to more than $2 billion. Earlier, the U.S. Vision Care operation had recorded 22 percent compound annual revenue growth during his leadership, against a market described as flat. These are operating measures. They tell us about the business he was managing before the startup chapter, when growth had to appear in the accounts rather than remain a promise in a presentation.
That experience matters to the sequence that followed. Someone accustomed to managing an existing enterprise arrives at a startup with useful habits, but a different relationship to money. Revenue and financing ask different questions. One measures the business already in motion; the other determines how much time there is to get the next part working. In 2019, McKenna moved from Salix to Prometheus and encountered that distinction with considerable force.
Eight months is a different kind of education
He recalled joining Prometheus believing it had 20 months of cash runway. The actual figure was fewer than eight. His finance chief explained the consequence of failing to raise more: bankruptcy, creditors taking the assets, and employees losing their jobs. McKenna asked, “What’s behind Door No. 2?” The answer was to raise the money.
The anecdote is funny only at a safe distance. At the time, the calendar was an operating constraint. A leader can describe a future with confidence, but payroll insists on discussing the present. Over the next four years, Prometheus raised more than $1 billion in private and public financing. It went public in 2021. By June 2023, Merck had completed the acquisition.
The transaction valued Prometheus at approximately $10.8 billion, with Merck paying $200 per share in cash. The number belongs to the acquisition of the company. Behind it lay the work of an organization whose continued existence had once depended on finding more funding. Those two points make a useful pair: the deadline at the beginning, the transaction at the end. Neither describes the whole experience alone.
during his leadership
completed June 2023
announced January 2026
Financing and acquisition value measure different things. These figures are separate milestones, not a measure of personal wealth.
A sale, then a reunion
After Prometheus, McKenna considered board and operating opportunities. Mirador began taking shape through a conversation in his family room with his chief scientific officer. Initial investor discussions contemplated $100 million or $200 million. Enthusiasm for the returning team helped bring the launch financing above $400 million. The contrast with the first fundraising journey was plain: this time, the relationships and shared experience were already there.
ARCH Venture Partners led the financing. OrbiMed and Fairmount invested early, alongside a wider group of investors. Several former Prometheus executives joined the new organization. The reunion made the launch more than a founder’s change of business stationery. People who had worked together through one company’s development were choosing to undertake the next job together.
“To me, the secret sauce here is the team.”
Mark C. McKenna
Mirador’s name means a vantage point or lookout in Spanish. It is an apt choice for a second venture: experience offers a different view of the terrain. The team still had to build a new company, but it could begin with working relationships already tested. The name supplies a pleasant image. The reunion supplies the more substantial explanation.
The work between the announcements
McKenna is Mirador’s founder, chairman and CEO. Around him, the organization includes people responsible for science, strategy, legal affairs, accounting, finance and the team itself. Those titles describe the range of work that must happen between the public milestones. A launch announcement can fit into a morning. Building the organization behind it occupies much longer.
He also serves as chairman of Apogee Therapeutics and a director of Spyre Therapeutics and NewAmsterdam Pharma. His investment work includes a venture partner role at ARCH and a senior advisory role at Fairmount Funds. He is also chief investment officer and managing director of McKenna Capital Partners. The list puts him in several different conversations about how companies are formed, financed and governed.
His public conversations extend to the stage and microphone. At Goldman Sachs’ 2024 Builders and Innovators Summit, he spoke with Dan Dees about the pace of innovation; the conversation was published in January 2025. A BioSpace interview appeared that March. The subject running through these appearances is the job he has chosen to keep doing: assembling the resources and organization for another venture.
Putting two disciplines on the same timetable
ASU is also a shared part of his life with Sheri. They met during their first year and both graduated in 2002. In 2025, their gift helped establish the McKenna Life Sciences, Business and Entrepreneurship Program. The design brings a finance degree, a natural science degree and an entrepreneurship and innovation certificate into one four-year course of study.
It is a practical response to the distance between having an idea and knowing how to organize a business around it. Students are offered mentorship, internships or research assistantships, industry events and corporate visits. The program connects subjects that a founder eventually has to discuss in the same room. A balance sheet and a scientific question can occupy different departments; a company still needs people able to understand both.
Two bachelor’s degrees. One certificate. A four-year plan.
McKenna received ASU’s Alumni Achievement Award in 2025, following the EY Entrepreneur Of The Year Pacific Southwest Award in 2023. In April 2026, the university announced him as an undergraduate business convocation speaker. Returning as a speaker and supporting a new program are different ways of revisiting the same place: one offers a story; the other helps students acquire tools for their own.
The next number comes with a job attached
In January 2026, Mirador disclosed a $250 million Series B completed in the third quarter of 2025. Total capital raised since launch exceeded $650 million. New investment included funds and accounts advised by T. Rowe Price Investment Management and Adage Capital Partners, with further participation from existing investors. McKenna emphasized capital efficiency and disciplined execution in the year ahead.
The sequence now stretches from a student reconsidering his major to an executive managing established businesses, a CEO raising startup capital, and a founder returning after a sale. Alongside it runs the education project with Sheri. Each chapter asks him to bring people with different skills into a shared undertaking.
The beach belongs in the story because the return was a choice. McKenna had reached a point at which another operating role required a reason. He found one in the work still ahead and the colleagues willing to join him. A happy ending had arrived. There was, inconveniently for his golf calendar, another company to build.